Veeva Systems delivers cloud-based software solutions focused on the life sciences industry. Its fiscal year ends January 31, so the June 3 release covers the first quarter of fiscal 2027, which ended April 30, 2026. Recent quarters have featured steady revenue growth supported by subscription increases in the Vault platform. This update should provide a clearer picture of demand for life sciences technology tools amid ongoing regulatory and operational shifts in pharmaceuticals and related fields. Solid results could strengthen confidence in continued expansion, whereas any adjustments to guidance might shape near-term investor views.
Analyst consensus for the fiscal 2027 first quarter lines up closely with the company’s own guidance. Revenue expectations sit near the middle of the $855 million to $858 million range. Non-GAAP fully diluted EPS estimates center on $2.13 to $2.14. For background, fiscal 2026 full-year revenue totaled $3,195.3 million, up 16% year over year. Key areas of focus include subscription revenue trends, operating margins, and any updates to the full-year fiscal 2027 outlook of $3.585 billion to $3.600 billion in total revenue. Past reactions have typically depended on whether results and the forward view beat or meet these levels.
Investor focus remains on Veeva’s capacity to maintain growth within its core life sciences segment. The stock has reacted to earnings beats or misses in earlier periods, with moves sometimes magnified by changes to forward guidance. Potential risks include variability in deal timing and broader spending patterns in healthcare technology. Positive notes on new customer wins or platform expansions could support a constructive tone, while any caution around macro conditions might moderate expectations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
After the release, attention will shift to any refinements in fiscal 2027 guidance and commentary on demand across Veeva’s product lineup. Subscription revenue momentum and customer retention rates stay central given the recurring revenue model.
Broader industry trends, such as pharmaceutical research and development spending, could shape results in future quarters. Margin trends and operating efficiency will also receive attention, along with updates on competitive positioning in cloud solutions for life sciences.
Investors should keep an eye on upcoming catalysts like potential new product announcements or partnership developments. Cost management and any effects from currency moves or regulatory changes in key markets are worth monitoring too.
When preparing for earnings like this one, I find it helpful to cross-reference fundamentals and technical signals with specialized tools. Tickeron’s AI Screener stands out for its ability to filter stocks and ETFs by technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows scanning thousands of names with customizable filters for industry, market cap, technical indicators, price patterns, and performance metrics, making it easier to spot relevant trade ideas and compare opportunities efficiently. AI Screener
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsFinancial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The 10-day moving average for VEEV crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VEEV as a result. In 54 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 33 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for VEEV entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry